Skip to main content

Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer

NCI - National Cancer Institute

open
OpenLast verified: 2026-06-18

About This Grant

PROJECT SUMMARY High grade serous ovarian cancer (HGSOC) is the most common histologic subtype of ovarian cancer and remains a deadly malignancy facing women. Late-stage diagnosis, development of chemoresistance and high rates of recurrence all contribute to the low five-year survival rate of advanced stage patients. Thus, identifying novel drivers of tumor progression and heterogeneity continue to be high research priorities. We find that enhanced mitochondrial fusion driven by a splice variant of the mitochondrial fission protein Drp1/DNM1L is a phenotype of HGSOC. Loss of exon 16 in the Exon16/17 variable domain, denoted as Drp1(-/17), leads to Drp1 redistribution from mitochondria to microtubules (MTs), and consequentially to dampened fission, a fused mitochondrial network and enhanced mitochondrial metabolism. Importantly, Drp1(-/17) expression drives proliferation, metastasis and chemoresistance, and this is of clinical significance as Drp1(-/17) high HGSOC tumors are associated with poor patient outcome. In the present proposal we will test the hypothesis that the extra-mitochondrial function of Drp1(-/17) contributes to HGSOC tumor progression and heterogeneity. Our preliminary data suggest that microtubules are not simply reservoirs for Drp1(-/17) to drive mitochondrial fusion, but that Drp1(-/17) has localized microtubule functions associated with its interaction and recruitment of the multi amino acyl tRNA synthase complex (MSC) to centrosomes. Based on observations that Drp1(-/17) high tumors display greater aneuploidy and copy number alterations leads us to predict that localized centrosome protein synthesis facilitated by the MSC interaction with Drp1(-/17) at centrosomes leads to centrosome amplification and chromosome segregation defects. Intriguingly, many of the amino acids that are required for tRNA charging by the MSC are derived from the TCA cycle. Coincidentally, we find that Drp1(-/17) cells display increased levels of TCA cycle metabolites and downstream amino acid. This leads us to predict that increased mitochondrial fusion due to Drp1(-/17) microtubule association drives TCA cycle flux, and that this works in concert with the MT-dependent function of Drp1(-/17) by supplying amino acids for the MSC. We further propose that de novo amino acid synthesis provides survival advantages to Drp1(-/17) under amino acid deprivation and that this contributes to tumor progression. Our work is conceptually innovative as it investigates the unique interplay between mitochondrial morphology, amino acid metabolism, and localized regulation of protein synthesis at the centrosome to chromosome instability, a common feature of HGSOC. The results from this work will have major impacts on our understanding of HGSOC tumor heterogeneity. Moreover, our research is the first demonstration that a splice variant of Drp1 has unique extra-mitochondrial functions in a pathophysiologic context.

Grant Summary

Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer is a NCI - National Cancer Institute grant providing up to $639K for university, nonprofit, healthcare org. Applications are due 2031-05-31 (open). Check eligibility and apply with FindGrants.

Focus Areas

health research

Eligibility

universitynonprofithealthcare org

How to Apply

Funding Range

Up to $639K

Deadline

2031-05-31

Complexity
High
  1. 1Confirm your organization is eligible for Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer from NCI - National Cancer Institute, checking organization type, location, and any population or project requirements.
  2. 2Gather the required documents and information, including your organization details, project plan, and budget figures.
  3. 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
  4. 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NCI - National Cancer Institute before the deadline.
This record is a past award, contract, or funder profile — useful for research, but not an open grant application. Check the original source for current opportunities from this funder.

Don't want to draft it yourself?

We'll draft the complete application against NCI - National Cancer Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.

AI Requirement Analysis

Detailed requirements not yet analyzed

Have the NOFO? Paste it below for AI-powered requirement analysis.

0 characters (min 50)

Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer: Frequently Asked Questions

Who is eligible for the Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer?

Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer is offered by NCI - National Cancer Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.

How much funding does the Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer provide?

Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer provides up to $639K per award from NCI - National Cancer Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.

When is the Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer deadline?

Applications for Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer are due 2031-05-31 (open). Because deadlines can change, verify the date with the funder, NCI - National Cancer Institute, and give yourself enough time to prepare a complete, competitive application before the close date.

How do you apply for the Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer?

To apply for Non-canonical functions of the mitochondrial fission protein Drp1 in ovarian cancer, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NCI - National Cancer Institute.

Browse More Grants